IRIS - Res&Arch Institutional Research Information System - Research & Archive

SPORTOLETTI, PAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.302
AS - Asia 4.086
EU - Europa 3.524
SA - Sud America 696
Continente sconosciuto - Info sul continente non disponibili 461
AF - Africa 115
OC - Oceania 6
Totale 15.190
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.958
SG - Singapore 1.892
IT - Italia 1.162
CN - Cina 593
IE - Irlanda 580
BR - Brasile 514
HK - Hong Kong 478
RU - Federazione Russa 412
VN - Vietnam 407
DE - Germania 241
FR - Francia 201
FI - Finlandia 170
GB - Regno Unito 148
SE - Svezia 138
CA - Canada 136
KR - Corea 132
UA - Ucraina 131
BD - Bangladesh 118
IN - India 110
AR - Argentina 63
MX - Messico 62
RO - Romania 53
TR - Turchia 51
NL - Olanda 49
AT - Austria 44
IQ - Iraq 35
UZ - Uzbekistan 35
BE - Belgio 33
PL - Polonia 33
PK - Pakistan 30
CO - Colombia 29
ZA - Sudafrica 28
CR - Costa Rica 27
ID - Indonesia 27
JP - Giappone 25
ES - Italia 24
EC - Ecuador 23
GT - Guatemala 23
CZ - Repubblica Ceca 22
PH - Filippine 22
VE - Venezuela 21
CH - Svizzera 18
LT - Lituania 18
SA - Arabia Saudita 17
EG - Egitto 15
PE - Perù 15
SV - El Salvador 15
TT - Trinidad e Tobago 14
HN - Honduras 12
JO - Giordania 12
MY - Malesia 12
PR - Porto Rico 12
GP - Guadalupe 11
MA - Marocco 11
NI - Nicaragua 11
CL - Cile 10
IL - Israele 10
SC - Seychelles 10
ET - Etiopia 9
JM - Giamaica 9
TH - Thailandia 9
AZ - Azerbaigian 8
CW - ???statistics.table.value.countryCode.CW??? 8
KE - Kenya 8
UY - Uruguay 8
AL - Albania 7
CI - Costa d'Avorio 7
IR - Iran 7
KZ - Kazakistan 7
LB - Libano 7
NP - Nepal 7
PT - Portogallo 7
PY - Paraguay 7
TN - Tunisia 7
BO - Bolivia 6
EE - Estonia 6
KG - Kirghizistan 5
PS - Palestinian Territory 5
DK - Danimarca 4
DO - Repubblica Dominicana 4
PA - Panama 4
AO - Angola 3
AU - Australia 3
GE - Georgia 3
GR - Grecia 3
HR - Croazia 3
KW - Kuwait 3
NZ - Nuova Zelanda 3
QA - Qatar 3
SK - Slovacchia (Repubblica Slovacca) 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AE - Emirati Arabi Uniti 2
AM - Armenia 2
BY - Bielorussia 2
BZ - Belize 2
DZ - Algeria 2
EU - Europa 2
IM - Isola di Man 2
KH - Cambogia 2
LV - Lettonia 2
Totale 14.706
Salva come PNG Salva come JPEG
Città #
Singapore 1.399
San Jose 705
Chandler 594
Dublin 572
Ashburn 550
Perugia 490
Hong Kong 474
San Mateo 384
Santa Clara 243
Boardman 207
Council Bluffs 203
Dong Ket 140
Altamura 131
Lauterbourg 131
Moscow 129
Seoul 129
Munich 117
Princeton 116
Beijing 114
Los Angeles 109
Medford 108
Lawrence 101
New York 101
Ho Chi Minh City 88
Ann Arbor 81
Wilmington 68
Hanoi 66
Andover 63
Helsinki 63
Jacksonville 62
Dallas 58
Piscataway 57
Turku 56
São Paulo 50
The Dalles 50
Rome 45
Bucharest 44
Milan 40
Montreal 36
Houston 34
Brussels 33
North Bergen 33
Phoenix 31
Brooklyn 30
Toronto 29
Des Moines 28
Frankfurt am Main 27
Dearborn 26
San José 26
Nuremberg 25
Redmond 25
Shanghai 25
Tokyo 25
Mexico City 24
Orem 24
Foligno 23
Vienna 23
Warsaw 23
Amsterdam 22
Tashkent 22
Atlanta 21
Hefei 21
London 21
Belo Horizonte 20
Charlotte 20
Chicago 20
San Paolo di Civitate 20
Norwalk 19
Rio de Janeiro 19
Guatemala City 18
Riverbank 18
Chennai 17
Denver 17
Redwood City 17
Barnet 16
Buffalo 16
Assisi 15
Haiphong 15
Manchester 15
Naples 15
San Francisco 15
San Salvador 15
Izmir 14
Philadelphia 14
Saint Petersburg 14
Stockholm 14
Baghdad 13
Johannesburg 13
Ankara 12
Guangzhou 12
Menlo Park 12
Mumbai 12
New Orleans 12
Amman 11
Brno 11
Managua 11
Bologna 10
Brasília 9
Falkenstein 9
Falls Church 9
Totale 9.334
Salva come PNG Salva come JPEG
Nome #
BCOR gene alterations in hematological diseases 209
Bcor deficiency perturbs erythro-megakaryopoiesis and cooperates with Dnmt3a loss in acute erythroid leukemia onset in mice 193
Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells 191
Bepridil exhibits anti-leukemic activity associated with NOTCH1 pathway inhibition in chronic lymphocytic leukemia 189
Constitutive phosphorylation of the active Notch1 intracellular domain in chronic lymphocytic leukemia cells with NOTCH1 mutation. 188
A mast cell-ILC2-Th9 pathway promotes lung inflammation in cystic fibrosis 181
Immune correlates of protection by vaccine against SARS-CoV-2 in patients with chronic lymphocytic leukaemia 178
Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity? 174
Notch1 modulates mesenchymal stem cells mediated regulatory T-cell induction 169
Activated autologous T cells exert an anti-B-cell chronic lymphatic leukemia effect in vitro and in vivo. 168
NOTCH1 inhibition prevents GvHD and maintains GvL effect in murine models 157
Decreased NOTCH1 Activation Correlates with Response to Ibrutinib in Chronic Lymphocytic Leukemia 150
ARSENIC TRIOXIDE AND ALL-TRANS-RETINOIC ACID TARGET NPM1 MUTANT ONCOPROTEIN LEVELS AND INDUCE APOPTOSIS IN NPM1-MUTATED AML CELLS 148
NPM1 AND FLT3-ITD MUTATIONS SINERGISTICALLY INDUCE GATA1 EPIGENETIC SILENCING IN A AML MOUSE MODEL 146
Notch signaling sustains the expression of Mcl-1 and the activity of eIF4E to promote cell survival in CLL 146
GSK3β is a critical, druggable component of the network regulating the active NOTCH1 protein and cell viability in CLL 143
Wnt/beta-Catenin Signaling Induces Integrin alpha 4 beta 1 in T Cells and Promotes a Progressive Neuroinflammatory Disease in Mice 142
Mutant NPM1 Maintains the Leukemic State through HOX Expression 142
NOTCH1 Aberrations in Chronic Lymphocytic Leukemia. 142
Germline NPM1 mutations lead to altered rRNA 2′-O-methylation and cause dyskeratosis congenita 141
NOTCH1 Activation Negatively Impacts on Chronic Lymphocytic Leukemia Outcome and Is Not Correlated to the NOTCH1 and IGHV Mutational Status 140
Acute myeloid leukemia with mutated NPM1: diagnosis, prognosis and therapeutic perspectives. 139
GATA1 epigenetic deregulation contributes to the development of AML with NPM1 and FLT3-ITD cooperating mutations 139
NK Cells in Chronic Lymphocytic Leukemia and Their Therapeutic Implications 134
Human stromal cells engineered with interleukin-7 enhance the survival of naive T lymphocytes. 133
Mesenchymal cells: a vehicle for gene therapy 132
The NOTCH1/CD39 axis: A Treg trip-switch for GvHD 130
Clinical-Grade Expanded Regulatory T Cells Prevent Graft-versus-Host Disease While Allowing a Powerful T Cell Dependent Graft-versus-Leukemia Effect in Murine Models 130
Blockade of Oncogenic NOTCH1 With the SERCA Inhibitor CAD204520 in T Cell Acute Lymphoblastic Leukemia 129
Clinical-Grade Expanded Regulatory T Cells Are Enriched with Highly Suppressive Cells Producing IL-10, Granzyme B, and IL-35 128
NPM1 AND FLT3-ITD MUTATIONS COOPERATE TO IMPAIR HEMATOPOIETIC STEM/PROGENITOR CELLS DIFFERENTIATION AND DEREGULATE GATA1 IN A MOUSE MODEL OF AML 127
IL-4-dependent Jagged1 expression/processing is associated with survival of chronic lymphocytic leukemia cells but not with Notch activation. 125
The radiosensitizer Silver nanoparticles effects are prevent to ion channel blocker DIDS in U251 human glioblastoma cell line. 124
Isolation and characterization of a new human T regulatory cell subset from peripheral blood CD4+ T lymphocyte 123
NOTCH1 Is Aberrantly Activated in Chronic Lymphocytic Leukemia Hematopoietic Stem Cells. 123
CD4(+) CD25(low) GITR(+) cells: a novel human CD4(+) T-cell population with regulatory activity. 123
Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. 122
Lack of glucocorticoid-induced leucine zipper (GILZ) deregulates B-cell survival and results in B-cell lymphocytosis in mice 122
Cytogenetic/mutation profile of chronic lymphocytic leukemia/malignant melanoma collision tumors of the skin 122
A revised NOTCH1 mutation frequency still impacts survival while the allele burden predicts early progression in chronic lymphocytic leukemia 121
Dactinomycin induces complete remission associated with nucleolar stress response in relapsed/refractory NPM1-mutated AML 121
Prolonged XPO1 inhibition is essential for optimal antileukemic activity in NPM1-mutated AML 119
Interleukin-7-engineered mesenchymal cells: in vitro effects on naive T-cell population. 119
Ibrutinib treatment of a patient with relapsing chronic lymphocytic leukemia and sustained remission of Richter syndrome 119
Dissecting Clonal Hematopoiesis in Tissues of Classical Hodgkin Lymphoma Patients 119
T regulatory cell separation for clinical application. 118
The glucocorticoid-induced TNF receptor family-related protein (GITR) is critical to the development of acute pancreatitis in mice 116
BRAF mutations in hairy-cell leukemia. 116
A powerful molecular synergy between mutant Nucleophosmin and Flt3-ITD drives acute myeloid leukemia in mice. 115
IN VITRO AND IN VIVO ANTILEUKEMIC ACTIVITY OF BEPRIDIL IN CHRONIC LYMPHOCYTIC LEUKEMIA IS ASSOCIATED WITH INHIBITION OF THE NOTCH1 PATHWAY 114
A novel NOTCH1 PEST domain mutation in a case of Chronic Lymphocytic Leukemia 113
BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity 112
Richter's transformation in the heart 111
Lessons, Challenges and Future Therapeutic Opportunities for PI3K Inhibition in CLL 111
CURCUMIN EXHIBITS IN VITRO AND IN VIVO ANTI-LEUKEMIC ACTIVITY INTERFERING WITH THE NOTCH1 PATHWAY AND INDUCING ENDOPLASMIC RETICULUM STRESS IN CHRONIC LYMPHOCYTIC LEUKEMIA 109
Functions of the native NPM1 protein and its leukemic mutant 108
The human NPM1 mutation A perturbs megakaryopoiesis in a conditional mouse model. 107
Novel NPM1 exon 5 mutations and gene fusions leading to aberrant cytoplasmic nucleophosmin in AML 107
Case Report: Contrasting BCL2 Upregulation With Venetoclax in a Case of Refractory Lymphomatoid Papulosis and Progressive Chronic Lymphocytic Leukemia 107
A pro-inflammatory environment in bone marrow of Treg transplanted patients matches with graft-versus-leukemia effect 105
Synthesis and characterization of UiO-66 metal-organic frameworks nanoparticles and their evaluation as drug delivery carriers in U251 glioblastoma cells 105
BEPRIDIL IS A POTENT NOTCH1 INHIBITOR AND EFFICIENTLY INDUCES APOPTOSIS IN CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL) CELLS in vitro AND in vivo 104
A curious novel combination of nucleophosmin (Npm1) gene mutations leading to aberrant cytoplasmic dislocation of npm1 in acute myeloid leukemia (aml) 102
Therapeutic Targeting Potential of Novel Silver Nanoparticles Coated with Anti-CD20 Antibody against Chronic Lymphocytic Leukemia 101
A NOVEL MECHANISM FOR NOTCH1 ACTIVATIONIN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS: INVOLVEMENT OF NOTCH1 ENDOSOMAL TRAFFICKING AND ALTERATIONS IN RAB PROTEINS 101
A genetic platform to model sarcomagenesis from primary adult mesenchymal stem cells 101
NOTCH1 PEST domain mutation is an adverse prognostic factor in B-CLL. 99
NOTCH and NF-κB interplay in chronic lymphocytic leukemia is independent of genetic lesion. 99
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study 98
Glucocorticoidi-Induced TNFR family Related gene (GITR) enhances dendritic cell activity 97
Mutational landscape of AML with normal cytogenetics: biological and clinical implications 96
Mouse models of NPM1-mutated acute myeloid leukemia: biological and clinical implications 96
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases 96
Catalase prevents DNA damage and cationic current activation by silver nanoparticles in U251 human glioblastoma cell line 95
Interleukin 7-engineered stromal cells: a new approach for hastening naive T cell recruitment 94
Mesenchymal cells recruit and regulate T regulatory cells. 93
NPM1-mutated acute myeloid leukemia: from bench to bedside 93
Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group 93
Venetoclax plus azacitidine as genetic-driven bridge-to-transplant therapy for IDH2-mutated acute myeloid leukaemia (AML) refractory to intensive chemotherapy: proof-of-concept case reports 90
FLT3-targeted therapy restores GATA1 pathway function in NPM1/FLT3-ITD mutated acute myeloid leukaemia 90
Identification and Characterization of Novel Rare Nucleophosmin (NPM1) Gene Mutations in Acute Myeloid Leukemia (AML) By a Combinatorial Approach of Immunohistochemistry and Molecular Analyses 90
Identification of an Epi-metabolic dependency on EHMT2/G9a in T-cell acute lymphoblastic leukemia 88
Loss of bone mineral density and secondary hyperparathyroidism are complications of autologous stem cell transplantation. 88
Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib 88
Nanotechnology Advances in the Detection and Treatment of Lymphoid Malignancies 87
A DYSREGULATED, DRUGGABLE PP2A/AKT/GSK3 beta AXIS SUSTAINS NOTCH1 SIGNALING IN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS 85
Uncommon lymphoplasmacytic lymphoma with IgA paraproteinemia: a challenging clinical diagnosis solved by MYD88 mutation analysis. 85
NOTCH-1 ACTIVATION AND SUBCLONAL MUTATION NEGATIVELY IMPACT ON CHRONIC LYMPHOCYTIC LEUKEMIA OUTCOMES 84
NOTCH1-mutated chronic lymphocytic leukemia displays high endoplasmic reticulum stress response with druggable potential 81
High rate of durable responses with undetectable minimal residual disease with frontline venetoclax and rituximab in young and fit patients with chronic lymphocytic leukemia and an adverse biologic profile: results of the GIMEMA phase II LLC1518 - 'Veritas' study 81
Venetoclax in CLL patients who progress after B-cell Receptor inhibitor treatment: a retrospective multi-centre Italian experience 81
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study 81
NOTCH1 Aberrant Activation Is a Common Nonmutational Early Event in Chronic Lymphocytic Leukemia Hematopoietic Stem-Cells 80
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials 80
Recurrent primary plasmacytoma of the eyelid with rapid regional metastasis. 79
Starry sky pattern predicts RAS pathway activation in NPM1‐mutated acute myeloid leukemia 78
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus 78
Acalabrutinib in High-Risk Chronic Lymphocytic Leukaemia Naïve Patients: An Italian Multicenter Retrospective Observational Real-Life Experience 77
The landscape of BRAF transcript and protein variants in human cancer. 77
The leukemia-associated cytoplasmic nucleophosmin mutant is an oncogene with paradoxical functions: Arf inactivation and induction of cellular senescence. 77
Totale 11.717
Salva come PNG Salva come JPEG
Categoria #
all - tutte 70.851
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 70.851
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022835 0 0 0 0 26 9 18 226 30 138 210 178
2022/20231.946 111 371 18 183 140 195 11 85 708 8 81 35
2023/2024918 40 81 52 35 6 24 282 10 52 31 137 168
2024/20252.398 77 195 63 81 293 142 211 172 478 109 366 211
2025/20265.286 360 303 237 597 741 482 902 324 554 491 159 136
2026/20271.926 151 199 351 1.001 224 0 0 0 0 0 0 0
Totale 15.190